Selection from HEOR Bibliography
| Search criteria | ||||
| Singapore |
||||
| High prevalence of comorbidities and contraindicated medications in hepatitis C patients in Japan | ||||
| T Tsutsumi 1, Eliza Kruger, Seng Tan, Hiroshi Yotsuyanagi | ||||
| 1) QuintilesIMS Singapore | ||||
| Journal of Viral Hepatitis |
||||
| , Article | ||||
| , Singapore | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2017 | English | , Budget impact | |
| Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore | ||||
| Goh SY1, Tan SC2, Lim LC3, Chua B4, Hunt B5 | ||||
| 1 Department of Endocrinology, Singapore General Hospital, Singapore 2 Health Economics & Outcomes Research, IMS Health Asia Pacific, Singapore 3 Department of Medicine, Alexandra Hospital, Singapore 4 Department of Vascular Surgery, Singapore General Hospital, Singapore 5 Ossian Health Economics and Communications, Switzerland | ||||
| Journal of Diabetology, February 2015; 1:2 |
||||
| , Online article | ||||
| , Singapore | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost effectiveness | |
| Budget Impact analysis of wider adoption of Biphasic Insulin Aspart (Biasp) in the treatment of type 2 Diabetes Mellitus (T2dm): A perspective of patients treated by public providers in Singapore | ||||
| Tan SC1, Matzen P2, Khoo SP2 | ||||
| 1 IMS Asia Pacific, Singapore 2 Novo Nordisk Pharma Malaysia, Kuala Lumpur, Malaysia 3 Novo Nordisk Pharma Singapore, Singapore | ||||
| ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
| , Poster | ||||
| , Singapore | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Budget impact | |
| Drug access through sharing public and individual responsibilities in the public healthcare system of Singapore | ||||
| Tan SC1, Low PY2, Chia MX2 | ||||
| 1IMS Asia Pacific, Singapore, Singapore, 2IMS Health Asia, Singapore, Singapore | ||||
| ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
| , Poster | ||||
| , Singapore | ||||
| Abstract: http://www.ispor.org/Event/ProgramList/2014Beijing?type=Poster&sess=III&acode=PHP | ||||
| Condition | Year | Language | Analysis type | |
| , Health policy | 2014 | English | , Review | |
| The cost-effectiveness of travoprost preserved with polyquad® in newly treated open-angle glaucoma patients in 7 Asian countries. | ||||
| Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
| 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , India, Malaysia, Singapore, South Korea, Thailand | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Cost effectiveness | |
| Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. | ||||
| Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
| 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Burden of illness | |
| Asthma control and its direct healthcare costs: findings using a derived Asthma Control Test (ACT) score in eight Asia-Pacific areas. | ||||
| Lai CKW1 Kuo S-H2 de Guia T3 Lloyd A4, Williams AE5, Spencer MD5 | ||||
| 1 Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 National Taiwan University Hospital, Taipei, Taiwan 3 Philippine Heart Centre, Quezon City, The Philippines 4 Fourth Hurdle Consulting Ltd, London, UK 5 GlaxoSmithKine R&D, Greenford, UK | ||||
| European Respiratory Review 2006; 15:(98): 24-29 |
||||
| , Manuscript in preparation | ||||
| , China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Vietnam | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2006 | English | , Cost of illness | |